Updates on the diagnosis and management of multicentric Castleman disease

Ya-Ju Wu; Kuei-Ying Su

doi:10.4103/tcmj.tcmj_15_20

Updates on the diagnosis and management of multicentric Castleman disease

Tzu Chi Med J. 2020 Jul 29;33(1):22-28. doi: 10.4103/tcmj.tcmj_15_20. eCollection 2021 Jan-Mar.

Authors

Ya-Ju Wu¹, Kuei-Ying Su^{2

3}

Affiliations

¹ Division of Critical Care Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
² Division of Rheumatology and Immunology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
³ School of Medicine, Tzu Chi University, Hualien, Taiwan.

Abstract

Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disease. The diagnosis of this disease is typically challenging and requires collaboration between clinicians and pathologists. Moreover, it is important to exclude other diseases (such as malignancies, autoimmune diseases, and infectious diseases) that have similar clinical manifestations and pathological findings. Patients with untreated severe MCD have high mortality due to devastating cytokine storms. Thus, early diagnosis and prompt treatment is a key imperative. The diagnosis of MCD is based on the clinical signs of systemic inflammation, serological tests, and typical pathological features. In this review article, we provide an overview of MCD with a focus on the emerging evidence pertaining to its diagnosis and treatment.

Keywords: Anasarca; Anti-CD20 monoclonal antibody; Fever; Human herpesvirus-8; Interleukin-6 targeted therapy; Multicentric Castleman disease; Reticulin fibrosis; Thrombocytopenia; and Organomegaly syndrome.

Publication types

Review